Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial

Komolmit, Piyawat; Charoensuk, Kriangsak; Thanapirom, Kessarin; Suksawatamnuay, Sirinporn; Thaimai, Panarat; Chirathaworn, Chintana; Poovorawan, Yong

doi:10.1371/journal.pone.0174608

Cited by 31 publications

(23 citation statements)

References 42 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optimal vitamin D levels may attenuate this virulent mechanism. In vivo studies have shown that the expression of DPP4/CD26 was significantly reduced after the correction of 25(OH)D deficiency [ 104 ]. These findings suggest that vitamin D supplementation is promising for the management of this new viral disease.…”

Section: Vitamins and Immune Systemmentioning

confidence: 99%

Effective Immune Functions of Micronutrients against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

The third coronavirus outbreak in the last two decades has caused significant damage to the world’s economy and community health. The highly contagious COVID-19 infection has affected millions of people to date and has led to hundreds of thousands of deaths worldwide. Aside from the highly infectious nature of SARS-CoV-2, the lack of a treatment or vaccine has been the main reason for its spread. Thus, it has become necessary to find alternative methods for controlling SARS-CoV-2. For the present review, we conducted an online search for different available nutrition-based therapies for previously known coronavirus infections and RNA-based virus infections as well as general antiviral therapies. These treatments have promise for combating COVID-19, as various nutrients and minerals play direct and indirect roles in the control and prevention of this newly emerged viral infection. The patients’ nutritional status with COVID-19 must be analyzed before administering any treatment, and nutritional supplements should be given to the affected individuals along with routine treatment. We suggest a potential interventional role of nutrients to strengthen the immune system against the emerging infection caused by COVID-19.

show abstract

Section: Vitamins and Immune Systemmentioning

confidence: 99%

Effective Immune Functions of Micronutrients against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some of the unique residues of S1 domain of COVID-19 spike glycoprotein are also presumed to interact with the ACE2 protein [ 58 ]. The expression of the DPP-4/CD26 receptor has been shown to be reduced significantly in vivo upon the correctness of vitamin D insufficiency [ 59 ]. However, there is insufficient evidence to elucidate the effect, if any, of sustained DPP-4 inhibition (as can be achieved through the correction of vitamin D insufficiency or through the use of DPP-4 inhibitors used in the treatment of diabetes) on coronavirus infections.…”

Section: Mechanism Behind Vitamin D’s Possible Protective Role Againsmentioning

confidence: 99%

Vitamin D in COVID - 19: Dousing the fire or averting the storm? – A perspective from the Asia-Pacific

Chandran¹,

Maung²,

Mithal³

et al. 2020

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

COVID-19, the acute respiratory tract infection (RTI) caused by the Coronavirus, Sars-CoV-2, has swept around the world. No country has been spared from its onslaught. Treatments that can reduce the risk of infection and mortality from the disease are desperately needed. Though high quality randomized controlled trials are lacking, some observational and interventional studies that explore the link between vitamin D and RTIs exist. Vitamin D modulates both innate as well as adaptive immunity and may potentially prevent or mitigate the complications associated with RTIs. Evidence linking vitamin D to COVID-19 include that the outbreak occurred in winter in the northern hemisphere at a time when vitamin D levels are lowest in resident populations, that blacks and minority ethnic individuals who are known to have lower levels of vitamin D appear to be disproportionately affected and have more severe complications from the disease, that vitamin D deficiency has been shown to contribute to acute respiratory distress syndrome and that case fatality rates increase with age and in populations with comorbid conditions such as diabetes, hypertension, and cardiovascular disease, all of which are associated with lower vitamin D levels. This narrative review summarizes the current knowledge about the epidemiology and pathophysiology of COVID-19, the evidence linking vitamin D and RTIs, especially COVID-19, the mechanistic reasons behind the possible protective effect of vitamin D in COVID-19, and the evidence with regard to vitamin D supplementation in RTIs. It concludes with some recommendations regarding supplementation of vitamin D in patients with COVID-19.

show abstract

“…Additionally, low serum VD levels were related to severe histological features and potentially predicted unfavorable treatment outcomes in patients with autoimmune hepatitis [ 29 ]. Among CHC patients, VD deficiency has several detrimental effects, including dysregulation of T-cell functions, resulting in lower response rates of the HCV genotype 1 to pegylated interferon and RBV treatment [ 14 , 30 ]. However, the revolutionization of HCV treatment with DAA has improved the overall curative rate to nearly 100% [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels. Methods Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled. Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes and liver stiffness measurements (LSM) were assessed at baseline. Blood samples for 25(OH)VD and the procollagen type III N-terminal peptide (P3NP) were collected at baseline, 24 and 48 weeks. LSMs were re-evaluated at 48 weeks. Serum 25(OH)VD levels < 30 ng/mL were defined as VD insufficiency/deficiency. Paired t-tests were used for statistical analyses. Results Among 80 patients, the mean age was 57.7 ± 10.5 years, and 52.5% were men. The mean VL was 6.1 ± 0.7 logIU/mL with genotype 1 predominance (55%). All patients achieved sustained virological response. The alanine aminotransferase levels decreased from 79.9 ± 53.3 U/L at baseline to 25.7 ± 17.2 and 22.3 ± 11.0 U/L at 24 and 48 weeks, respectively (p < 0.001). The mean LSM decreased from 19.2 ± 15.3 to 11.7 ± 8.0 kPa at 48 weeks (p < 0.001). The P3NP levels decreased from 43.6 ± 22.0 ng/mL before treatment to 35.7 ± 21.1 and 29.4 ± 15.0 ng/mL at 24 and 48 weeks, respectively (p < 0.001). The proportions of VD insufficiency/deficiency were 72.5%, 91.3%, and 86.5% at baseline, 24 and 48 weeks, respectively. The 25(OH)VD levels decreased from 26.3 ± 10.7 ng/mL at baseline to 20.8 ± 8.1 and 20.8 ± 8.5 ng/mL at 24 and 48 weeks, respectively (p < 0.001). Conclusions Curative treatment with DAA attenuated the liver stiffness and inflammation but did not improve VD levels. Over 80% of patients remained VD insufficient/deficient. Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear. Trial registration The Thai Clinical Trial Registry as TCTR20161025001 (31 October 2016). http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2136.

show abstract

Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial

Cited by 31 publications

References 42 publications

Effective Immune Functions of Micronutrients against SARS-CoV-2

Effective Immune Functions of Micronutrients against SARS-CoV-2

Vitamin D in COVID - 19: Dousing the fire or averting the storm? – A perspective from the Asia-Pacific

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

Contact Info

Product

Resources

About